Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for **90** percent of all liver cancers.

Cancer types and incidence



More than

866,100 people around the world are diagnosed with liver

cancer each year.

Approximately 1 in 13 cancer deaths are due to liver cancer.



Liver cancer is the third leading cause of cancer mortality worldwide and occurs more often in men than women.


632,300

273,400 cases per year

Median age

At diagnosis

Source: SEER 2017-2021, 2018-2022



Common risk factors

Between 80 and 90 percent of all HCC cases worldwide are caused by infection with the Hepatitis B virus (HBV) or Hepatitis C virus (HCV). Other common risk factors include:



Chronic HCV/HBV infection











Certain genetic



Type 2 diabetes



Obesity



Non-alcoholic steatohepatitis (NASH)

Global incidence

Estimated numbers of annual liver cancer cases by region:

North America 48.500

Europe 88.900

607,400

Latin America & the Caribbean 42,800

73,800

Oceania 4,800

Source: GLOBOCAN 2022

Source: SEER 2014-2020

Signs and symptoms



Unintended weight loss



Loss of appetite



Nausea or vomiting



Enlarged liver and/or spleen



Abdominal pain and/or swelling



Itching



Yellowing of the skin and eyes

Potential benefits of early intervention

There are notable advantages of earlier diagnosis and treatment of HCC. These may include:



Improved survival outcomes



Increased quality of life



Lower cost of treatment

Treatment options

A patient's treatment options are largely dependent on stage of disease and may include:



Surgery



Immunotherapy



Radiation therapy



Chemotherapy



Tumor ablation or embolization



Targeted drug therapy